The HER2CLIMB-02 results could also be good news for Roche, which has seen its ADC come under strong competitive pressure from AstraZeneca and Daiichi Sankyo's rival HER2 ADC Enhertu (trastuzumab ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback